Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Medullary 2Neoplasm Metastasis 1

Interventions

pembrolizumab 284Carboplatin 216Cisplatin 148Paclitaxel 145Gemcitabine 145Bevacizumab 117Pemetrexed 114Docetaxel 103Oxaliplatin 79Cyclophosphamide 79Dexamethasone 78durvalumab 77atezolizumab 77Fluorouracil 77Nivolumab 75130-nm albumin-bound paclitaxel 71Fulvestrant 68Capecitabine 64Injections 63Cetuximab 63Leucovorin 60Rituximab 56fludarabine 52Lenalidomide 49Prednisone 46venetoclax 43Irinotecan 43Letrozole 40enzalutamide 39tislelizumab 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × vandetanib × 90 days × Clear all
NCT01298323 2026-04-17

Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment

Sanofi

Phase 3 Completed
205 enrolled 10 charts

Neoplasm Metastasis, Carcinoma, Medullary

NCT04211337 2026-03-19

LIBRETTO-531

Eli Lilly and Company

Phase 3 Active not recruiting
291 enrolled 16 charts 1 FDA

Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡